Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR T cells targeting CD19 + CD22 + CD20
- Development stage
- Unknown
- Lead developer
- Beijing Boren Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CAR T cells targeting CD19 + CD22 + CD20 is a **target-specific, investigational CAR-T-cell therapy descriptor** rather than a uniquely named commercial product or an assigned INN. In the cited Beijing Boren Hospital studies, it denotes sequential administration of engineered T-cell products directed against B-cell antigens CD19, CD22, and potentially CD20 for relapsed or refractory B-cell acute lymphoblastic leukemia, including relapse after allogeneic hematopoietic stem-cell transplantation. CAR-mediated recognition of these antigens activates cytotoxic T cells to eliminate malignant B cells; use of more than one antigen-directed CAR-T product is intended to reduce antigen-escape relapse. The publicly documented ChiCTR-ONC-17013648 program specifically reports sequential CD19 followed by CD22 CAR-T-cell treatment, while the broader CD19/CD22/CD20 wording should not be interpreted as confirmation of one uniquely defined trispecific CAR construct.
- Other names
- CAR T cells targeting CD19/CD22/CD20CAR-T cells targeting CD19/CD22/CD20
02
Targets
CD19 (B lymphocyte antigen CD19)CD20 (B-lymphocyte antigen CD20)CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on CAR T cells targeting CD19 + CD22 + CD20.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR T cells targeting CD19 + CD22 + CD20.